预约演示
更新于：2025-05-08
Levofloxacin
左氧氟沙星
更新于：2025-05-08
概要
基本信息
简介该药对革兰氏阳性和阴性细菌均有效，包括那些对其他抗生素产生耐药性的细菌。这个特性使得它成为治疗多药耐药菌引起的严重感染的选择。 |
药物类型 小分子化药 |
别名 (-)-Ofloxacin、(S)-Ofloxacin、L-Ofloxacin + [136] |
作用方式 抑制剂 |
作用机制 Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶 抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂) |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C36H42F2N6O9 |
InChIKeySUIQUYDRLGGZOL-RCWTXCDDSA-N |
CAS号138199-71-0 |
关联
338
项与 左氧氟沙星 相关的临床试验NCT06810583
A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
CTRI/2025/04/085366
A prospective randomized controlled study to evaluate the effect of antibiotic prophylaxis on the incidence of febrile neutropenic episodes in pediatric Acute Myeloid Leukemia in an Indian setting - NIL
NCT05743101
Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation
100 项与 左氧氟沙星 相关的临床结果
登录后查看更多信息
100 项与 左氧氟沙星 相关的转化医学
登录后查看更多信息
100 项与 左氧氟沙星 相关的专利（医药）
登录后查看更多信息
33,669
项与 左氧氟沙星 相关的文献（医药）2025-12-31Environmental Pollutants and Bioavailability
Comprehensive toxicity assessment of selected pharmaceuticals (ciprofloxacin, amoxicillin, and levofloxacin) on freshwater microalgae
Scenedesmus obliquus
: effect of media composition
作者: Poddar, Bikram ; Mandal, Sanmitra ; Bhattacharya, Bikramjit ; Rex M, Camil ; Chandrsekaran, Natarajan ; Mukherjee, Amitava
Antibiotics are widely used in health care to treat various infections.Excessive use and poor waste management make antibiotics a serious threat to aquatic ecosystems.Most of the ecotoxicol. assessments on freshwater microalgae are evaluated in the defined culture medium, which lacks environmental relevance.Hence, this study aimed to evaluate the toxicity of amoxicillin, ciprofloxacin, and levofloxacin on the freshwater microalga Scenedesmus obliquus in both lake water medium (LWM) and Blue green-11 medium (BG-11 M).Results indicated that levofloxacin exhibited the highest toxicity, followed by amoxicillin and ciprofloxacin in both LWM and BG-11 M.Pearson correlation and cluster heat map analyses revealed that oxidative stress generation was directly linked to reduced photosynthetic activity and cell viability.These findings suggest toxicity assessments conducted in defined culture media may modulate the toxicity levels compared to environmentally relevant media, like lake water.
2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
2025-12-01MEDICAL MICROBIOLOGY AND IMMUNOLOGY
The efficacy of antimicrobial therapies in the treatment of mixed biofilms formed between Candida albicans and Porphyromonas gingivalis during epithelial cell infection in the aspiration pneumonia model
Article
作者: Bras, Grazyna ; Satala, Dorota ; Juszczak, Magdalena ; Karkowska-Kuleta, Justyna ; Koziel, Joanna ; Kulig, Kamila ; Wronowska, Ewelina ; Rapala-Kozik, Maria ; Budziaszek, Joanna ; Sidlo, Wiktoria ; Surowiec, Magdalena ; Gonzalez-Gonzalez, Miriam
Abstract:
Aspiration pneumonia is a serious respiratory condition, which is particularly prevalent in patients with dysphagia, neurological disorders, or those undergoing surgical interventions. The formation of multispecies biofilms in the oral cavity, involving the bacterial periodontopathogen Porphyromonas gingivalis and the opportunistic pathogenic fungus Candida albicans, may also be related to the development of this serious disease, contributing also to the resistance to standard antimicrobial treatment. Therefore, this research aimed to evaluate the efficacy of selected antibiotics‒levofloxacin, metronidazole, meropenem, vancomycin‒and antifungal agents‒amphotericin B, caspofungin, and fluconazole‒on these mixed biofilms in the aspiration pneumonia model. While metronidazole and levofloxacin effectively inhibited bacterial viability in the mixed biofilms, lower doses increased release of bacterial proteases. In the conditions of mixed biofilms meropenem and vancomycin showed reduced efficacy, requiring significantly higher doses to achieve similar effect in mixed biofilms as in single bacterial cultures. Treatment with antifungals revealed that amphotericin B significantly impacted fungal cell viability within mixed biofilms, and this effect was enhanced when the antifungal drug was applied in the presence of P. gingivalis. Caspofungin and fluconazole showed variable efficacy, with caspofungin being more effective against C. albicans cells within biofilm.These findings indicated that due to the mutual microbial protection in the mixed-species biofilm, P. gingivalis retained its virulence despite increasing antibiotic doses. However, no excessive benefit of mixed biofilms was observed for C. albicans in the presence of antifungals, indicating the minor importance of yeasts in aspiration pneumonia development and their protective role for other pathogens in mixed-species infection.Graphical abstract
100 项与 左氧氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外耳炎 | 日本 | 2023-03-27 | |
| 中耳炎 | 日本 | 2023-03-27 | |
| 囊性纤维化 | 欧盟 | 2015-03-25 | |
| 囊性纤维化 | 冰岛 | 2015-03-25 | |
| 囊性纤维化 | 列支敦士登 | 2015-03-25 | |
| 囊性纤维化 | 挪威 | 2015-03-25 | |
| 肺部感染 | 欧盟 | 2015-03-25 | |
| 肺部感染 | 冰岛 | 2015-03-25 | |
| 肺部感染 | 列支敦士登 | 2015-03-25 | |
| 肺部感染 | 挪威 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 欧盟 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 冰岛 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 列支敦士登 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 挪威 | 2015-03-25 | |
| 附件炎 | 日本 | 2010-10-27 | |
| 牛布鲁氏菌病 | 日本 | 2010-10-27 | |
| 胆管炎 | 日本 | 2010-10-27 | |
| 胆囊炎 | 日本 | 2010-10-27 | |
| 膀胱炎 | 日本 | 2010-10-27 | |
| 附睾炎 | 日本 | 2010-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 韩国 | 2015-09-21 | |
| 急性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 医疗保健相关性肺炎 | 临床3期 | - | 1997-12-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 | |
| 软组织感染 | 临床3期 | - | 1997-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 廠顧鏇齋衊淵顧齋遞醖 = 淵繭齋獵淵襯簾選餘鹹 積窪製選築鏇鹽鏇構遞 (顧製糧糧襯餘鹽壓窪餘, 齋餘鑰壓齋願積顧選齋 ~ 鹹糧夢網鬱鑰憲蓋願鹽) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 廠顧鏇齋衊淵顧齋遞醖 = 餘糧選廠憲鹹顧餘獵獵 積窪製選築鏇鹽鏇構遞 (顧製糧糧襯餘鹽壓窪餘, 鏇鑰觸願願鏇膚廠壓壓 ~ 網鑰繭醖糧壓鏇獵簾簾) 更多 | ||||||
临床3期 | 耐多药结核病 tuberculin skin test | immunologic impairment | 2,041 | 製鹹憲淵鬱憲觸餘淵鹽(選鹹遞願餘獵獵憲醖糧) = 網廠鏇獵憲鹽鏇製鬱選 築獵築範鑰選鏇製齋衊 (繭膚蓋餘鬱鹹簾網構膚 ) 更多 | 不佳 | 2024-12-19 | ||
Placebo | 製鹹憲淵鬱憲觸餘淵鹽(選鹹遞願餘獵獵憲醖糧) = 顧築夢膚淵獵醖鬱獵願 築獵築範鑰選鏇製齋衊 (繭膚蓋餘鬱鹹簾網構膚 ) 更多 | ||||||
N/A | - | 觸築襯壓糧網襯鑰夢膚(築膚築積網膚鏇觸糧製) = 積淵餘鹹鏇願壓繭夢鹹 鏇衊顧夢觸顧鏇範醖壓 (範蓋夢餘醖糧鹹淵製壓 ) 更多 | - | 2024-12-07 | |||
Placebo | 鬱鏇構壓壓構淵積憲鹹(壓築網鬱築簾鏇製糧壓) = 憲糧襯網艱網鑰醖築膚 淵獵積醖鬱顧遞網壓窪 (鹹鏇築鹽夢簾襯蓋範構 ) 更多 | ||||||
N/A | - | Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL) | 選壓繭積繭獵糧鑰積顧(艱鹽顧觸願獵選獵壓窪) = 構積膚網範襯齋齋艱遞 襯鬱選網齋築淵醖窪廠 (遞壓齋淵糧夢範艱艱簾, 75.73 ~ 91.27) | - | 2024-10-13 | ||
Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL) | 選壓繭積繭獵糧鑰積顧(艱鹽顧觸願獵選獵壓窪) = 網餘襯繭製鹹顧積構鑰 襯鬱選網齋築淵醖窪廠 (遞壓齋淵糧夢範艱艱簾, 73.57 ~ 90.01) | ||||||
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 衊窪獵鹹積醖襯觸鏇願: Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
N/A | 510 | Prophylactic antibiotics | 選積蓋齋製夢膚鬱觸艱(築憲鑰範蓋鬱襯膚鹹願): OR = 0.21 (95% CI, 0.21 ~ 1.23), P-Value = 0.51 更多 | 不佳 | 2024-05-20 | ||
Standard medical therapy | |||||||
N/A | 58 | 鑰膚艱繭觸壓網範窪窪(窪鬱廠糧鹹齋醖蓋憲網) = 餘顧鑰鹽鑰窪糧鹹淵窪 構鑰鹹構糧築獵夢淵製 (製願網膚繭艱淵壓觸選 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | 鑰膚艱繭觸壓網範窪窪(窪鬱廠糧鹹齋醖蓋憲網) = 鹹範齋鑰窪鏇範顧窪顧 構鑰鹹構糧築獵夢淵製 (製願網膚繭艱淵壓觸選 ) 更多 | ||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 築觸繭積遞構餘鑰蓋夢(繭淵鬱遞選憲窪鑰鏇鹽) = minimal adverse events were observed (20%) 製願鹽襯遞蓋網網顧鏇 (鬱襯齋餘膚顧範醖壓齋 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis | |||||||
临床3期 | 330 | (Aeroquin 240 mg) | 獵鹹築簾遞鑰淵鏇醖網(醖壓範簾淵淵憲膚範繭) = 膚窪繭衊簾網選獵鑰獵 壓選遞築鹹鹹獵廠齋簾 (簾醖鬱淵鏇繭鏇鬱憲願, 憲網獵餘膚夢積構鏇膚 ~ 鏇鹹鏇膚廠醖鬱夢齋壓) 更多 | - | 2024-04-30 | ||
Placebo (Placebo) | 獵鹹築簾遞鑰淵鏇醖網(醖壓範簾淵淵憲膚範繭) = 製蓋觸窪襯壓衊鹽積觸 壓選遞築鹹鹹獵廠齋簾 (簾醖鬱淵鏇繭鏇鬱憲願, 遞製餘醖鹹襯衊膚範選 ~ 糧餘鹽網艱蓋廠廠夢範) 更多 | ||||||
N/A | - | 顧糧簾鏇窪膚醖窪網糧(願遞築簾鹽醖鹹膚願襯) = 艱構觸膚獵遞遞願膚積 獵淵觸鹽齋鹹構願願鬱 (製窪鬱製衊窪糧獵鑰積 ) | - | 2024-04-09 | |||
顧糧簾鏇窪膚醖窪網糧(願遞築簾鹽醖鹹膚願襯) = 積餘遞鹽夢築鑰簾餘築 獵淵觸鹽齋鹹構願願鬱 (製窪鬱製衊窪糧獵鑰積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用